Stryker (SYK) Q1 2026 (USD): Adj. EPS 2.60 (exp. 2.98), Revenue 6bln (exp. 6.34bln)
Context
Stryker's Q1 2026 results falling short of both adjusted EPS and revenue expectations indicates potential concerns regarding the company's operational performance and growth trajectory. This miss could weigh on investor sentiment, especially in the health care sector, and may lead to downward pressure on its stock price as analysts reassess their outlook and targets going forward.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#STRYKER CORP#SYK.US#IMPORTANT#FOREX#EQUITIES#METALS#US SESSION#HEALTH CARE EQUIPMENT#METALS & MINING#HEALTH CARE EQUIPMENT & SUPPLIES#HEALTH CARE EQUIPMENT & SERVICES (GROUP)#S&P 500 INDEX#SYK#DXY#US EQUITIES